Braidwell LP Hille Vax, Inc. Transaction History

Braidwell LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$10.35 - $17.11 $12.9 Million - $21.3 Million	-1,245,839 Reduced 85.96%	203,407 $3.26 Billion
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $2.32 Million - $3.34 Million	200,000 Added 16.01%	1,449,246 $19.5 Billion
Q2 2023 Aug 14, 2023	SELL	$12.93 - $18.76 $4.8 Million - $6.96 Million	-370,970 Reduced 22.9%	1,249,246 $21.5 Billion
Q4 2022 Feb 14, 2023	BUY	$13.52 - $21.46 $21.9 Million - $34.8 Million	1,620,216 New	1,620,216 $27.1 Billion

40.5M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $58.8M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

Stay updated on Braidwell LP with notifications on news.